FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
13.0 Pkt. (24h)Health & MedicineOne-Off3Mon
KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle implizite Wahrscheinlichkeit
Ja 98%+13.0pt
Marktqualitat
47 / 100
Niedrige Qualität24h-Volumen
480,1 €
Liquidität
1268,4 €
Niedrige LiquiditätGeld / Brief
91.0% / 99.0%
Spread
8.0 pt
Breiter SpreadMarktdaten
Aktualisiert vor 9 Minuten
17. Juni 26, 21:30 UTC1. Jan. 27, 04:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRegeln
If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Abwicklung über:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Anitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own immune cells, reprogrammed in a laboratory to hunt and destroy cancer cells — think of it as taking a soldier from the patient's own army, giving it a custom-made targeting scope, and sending it back in.
- It is classified as a CAR-T (chimeric antigen receptor T-cell) therapy developed by Arcellx and commercialized in partnership with Gilead Sciences, designed to treat a blood cancer called multiple myeloma.
- In the trials studied here, it showed very high response rates, with nearly all treated patients responding to the therapy.
Offene Märkte
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Gesamtvolumen
- 15,6 Mio. €
- 24h-Volumen
- 18.288,2 €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Gesamtvolumen
- 1,6 Mio. €
- 24h-Volumen
- 5178,9 €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 weitere Ergebnisse
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Gesamtvolumen
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Gesamtvolumen
- 916.002,6 €
- 24h-Volumen
- 1515,1 €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 weitere Ergebnisse
- Gesamtvolumen
- 863.640,2 €
- 24h-Volumen
- 1039 €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Häufige Fragen
- Wie stehen die aktuellen Quoten für FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)?
- Kalshi bewertet Yes mit 98% (Stand: 8. September 2026).
- Wann wird FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) entschieden?
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) soll am 1. Januar 2027 entschieden werden.
- Wie wird FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) abgerechnet?
- Kalshi rechnet diesen Markt wie folgt ab: If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.